Infecciones en pacientes con artritis reumatoide: medicamentos moduladores de la respuesta biológica versus fármacos modificadores de la enfermedad. Seguimiento a un año

Abstract

Listen

Translate article

BackgroundDisease modifying anti-rheumatic drugs and biological disease modifying drugs are used to control inflammation and prevent progression of joint damage in rheumatoid arthritis. It is still controversial whether these drugs increase the incidence of infection in this disease. MethodsA retrospective cohort study was conducted on a population sample of 383 inpatients and outpatients from a university hospital and referral rheumatology tertiary hospital complex in northwestern Colombia. They were classified according to American College of Rheumatology 1987 classification criteria, with 83 in the biological therapy group, and 300 in the disease modifying antirheumatic drugs group, in order to establish the incidence and risk factors for serious and non-serious infections at 12 months follow-up. ResultsThe majority were females (85%). The biological therapy group presented a greater risk for non-serious [HR 1.73 (95% CI 1.07–2.77; P=.023)] and serious infections [HR 2.56 (95% CI 1.09–6.01; P=.030)]. This finding remained when adjusting for other variables associated with infection (number of disease modifying antirheumatic drugs received, methotrexate, leflunomide and steroids use, diabetes mellitus), with HR for non-serious infection [(1.67, 95% CI 1.05–2.70; P=.030)], and HR for serious infection [(2.67, 95% CI 1.12–6.34; P=.026)]. Chronic lung disease [HR 5.11 (95% CI 1.18–22.08; P=.029)] was an additional risk factor for serious infections. ConclusionsBiological therapy increases the risk of serious and non-serious infections at 12 months, compared to disease modifying drugs, in a group of patients with rheumatoid arthritis. The risk of serious infections also increases with the presence of chronic lung disease